HER2/neu Receptor Antagonist class drugs

6 results

  • herceptin

    (Trastuzumab)
    Genentech, Inc.
    Herceptin is indicated for the adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer in combination with paclitaxel, or as a single agent after previous regimens. It is also used with cisplatin and capecitabine for HER2-positive metastatic gastric cancer. Patient selection should utilize an FDA-approved diagnostic.
    Medication Details
    Drug Interactions

  • herceptin hylecta

    (Trastuzumab and hyaluronidase-oysk)
    Genentech, Inc.
    HERCEPTIN HYLECTA is indicated for adjuvant treatment of HER2 overexpressing breast cancer in adults, either as part of a combination regimen with specific chemotherapy agents or as a single agent after anthracycline-based therapy. It is also used for first-line and subsequent treatment of metastatic breast cancer.
    Medication Details
    Drug Interactions

  • herzuma

    (TRASTUZUMAB)
    Cephalon, Inc.
    HERZUMA is indicated for adults with HER2 overexpressing breast cancer, both in adjuvant and metastatic settings, and for metastatic gastric or gastroesophageal junction adenocarcinoma. Treatment modalities include combinations with specific chemotherapies or as a single agent, guided by FDA-approved diagnostics.
    Medication Details
    Drug Interactions

  • kadcyla

    (ADO-TRASTUZUMAB EMTANSINE)
    Genentech, Inc.
    KADCYLA is indicated for treating HER2-positive metastatic breast cancer in patients who have previously received trastuzumab and a taxane, or for early breast cancer in those with residual disease after neoadjuvant therapy. Patient selection should use an FDA-approved companion diagnostic.
    Medication Details
    Drug Interactions

  • margenza

    (margetuximab-cmkb)
    MacroGenics, Inc
    MARGENZA is indicated for treating adult patients with metastatic HER2-positive breast cancer, in combination with chemotherapy, who have previously received two or more anti-HER2 regimens, including one for metastatic disease.
    Medication Details
    Drug Interactions

  • phesgo

    (pertuzumab, trastuzumab, and hyaluronidase-zzxf)
    Genentech, Inc.
    PHESGO is indicated for combination with chemotherapy in adults with HER2-positive early breast cancer for neoadjuvant and adjuvant treatment, and for those with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy. Patient selection is based on an FDA-approved diagnostic test.
    Medication Details
    Drug Interactions